Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jan 03, 2024 1:29pm
RE:RE:Gail completed BOD’s Objectives
Sad? She did the job she was installed to do: shut-up and watch the price drop, then leave.
(80)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Jan 03, 2024 12:24pm
RE:Gail completed BOD’s Objectives
Can't say I disagree with this one. Except I think the PMN website is just fine. Dr. Farfel organized information/presentations well but tamped down marketing and had poor public speaking
...more
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development
posted May 02, 2024 9:00am by
Saturn Oil & Gas Inc.
-
|
Saturn has followed up its success in previous years drilling in Southeast Saskatchewan to enhance its IP30 initial production rates and overall return on invested capital. Saturn has recently finished drilling one gross (1.0 net) Open Hole Multi-Lateral ("OHML") well in the Viewfield area of Southeast Saskatchewan with eight horizontal legs of up to two miles each ...read more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jan 03, 2024 12:24pm
RE:RE:Gail completed BOD’s Objectives
I wonder what was the intended message with "who has stepped down to pursue other opportunities"? Is that to imply without saying that we didn't have to pay out on contract, or
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Jan 03, 2024 10:18am
RE:Gail completed BOD’s Objectives
Exactly, that's what makes this move "strategic".
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Jan 03, 2024 9:35am
Gail completed BOD’s Objectives
Early on arrival shut down Social Media, Company communications, old outdated WEB info. She did however complete objectives of taking the stock ro an all time low and was able to issue millions in new
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jan 03, 2024 7:00am
New Press Release - ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...
read article.
(80)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Dec 27, 2023 6:47pm
RE:RE: Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals
I think that the issue is more that they have not wanted to sell or lose control. Big pharma is letting them sweat and melt down and will gladly scoop up the patents if they go under.
...more
(2)
•••
Jumpinjackfast
X
View Profile
View Bullboard History
Comment by
Jumpinjackfast
on Dec 27, 2023 2:36pm
RE: Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals
Next Milestone is Delisting , complete garbage ran company always has been past crooks thought with there keys to the kingdom that big pharma would jump all over there technology. The plan was sell it
...more
(80)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Dec 27, 2023 1:15pm
Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals
https://www.nasdaq.com/articles/deutsche-bank-initiates-coverage-of-acumen-pharmaceuticals-abos-with-buy-recommendation Their $8 price target would but Acumen at a market cap of almost $500M. They
...more
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Dec 26, 2023 4:18pm
RE:RE:PMN to the moon, let's ride!
And so ends tax loss season, sure hope so anyway as I nibbled a bit.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Dec 20, 2023 7:00am
New Press Release - ProMIS Neurosciences Announces Publication on Novel Target for ALS
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). TORONTO, Ontario and CAMBRIDGE, Massachusetts, Dec. 20, 2023 (GLOBE NEWSWIRE...
read article.
(107)
•••
M101
X
View Profile
View Bullboard History
Comment by
M101
on Dec 18, 2023 4:27pm
RE:PMN to the moon, let's ride!
In Bidenomics AD is considered a feature not a bug.
(66)
•••
retiredcop
X
View Profile
View Bullboard History
Post by
retiredcop
on Dec 17, 2023 2:24pm
Performance based compensation
Goldtec can you post the name of a biotech or phrama company that has performance based compensation for its board and executive.. I cant seem to find any and I assume since you are
...more
(80)
•••
Gbathat
X
View Profile
View Bullboard History
Post by
Gbathat
on Dec 15, 2023 3:56pm
PMN to the moon, let's ride!
https://www.ihealthcareanalyst.com/global-alzheimers-disease-market/ The global market for Alzheimer’s disease estimated to reach $15.5 billion by 2031, growing at a staggering double-digit CAGR of
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results